Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
43 results about "Activating transcription factor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Activating transcription factor, ATF, is a group of bZIP transcription factors, which act as homodimers or heterodimers with a range of other bZIP factors. First, they have been described as members of the CREB/ATF family, whereas it turned out later that some of them might be more similar to AP-1-like factors such as c-Jun or c-Fos. In general, ATFs are known to respond to extracellular signals and this suggests an important role that they have in maintaining homeostasis. Some of these ATFs, such as ATF3, ATF4, and ATF6 are known to play a role in stress responses. Another example of ATF function would be ATFx that can suppress apoptosis.
Methods of treating metabolic disorders
InactiveUS20090137671A1High sensitivityBiocideMetabolism disorderInsulin sensitivityActivating receptors
A method of increasing the insulin sensitivity of insulin resistant cells includes administering to the cells an amount of all-trans-retinoic acid effective to activate transcription factor perosixome proliferator-activated receptor (PPAR) β / δ of the cells.
Owner:CASE WESTERN RESERVE UNIV
Enhancer Hr3
ActiveCN102492692AIncrease transcriptional activityImprove expression levelVector-based foreign material introductionDNA preparationRestriction sitePromoter
The invention relates to enhancer Hr3 adopting the nucleotide sequence shown in the SEQIDNO: 1. The enhancer Hr3 can be used for preparing and recombining heterologous protein by bombyx mori. The invention further relates to a recombination carrier containing the enhancer Hr3, and the recombination carrier is prepared in such a manner that the enhancer Hr3 is connected with a Nco1 restriction site at the upstream of a promoter of a carrier containing no enhancer through the Nco1 restriction site of the enhancer Hr3. In the invention, functional elements such as the first grade enhancer, activating transcription factor IE1, untranslated region sequences (5' UTR and 3' UTR) and the like which are expressed by intensifier are identified in the cellular level, and an efficient and stable sericin I expression system is built by integrating optimum elements on the basis, so that efficient expression recombination heterologous protein can be made of middle silk gland of transgenic bombyx mori.
Owner:SOUTHWEST UNIVERSITY
Bacillus subtilis polygene editing and expression adjusting and controlling system based on CRISPR Cpf1
ActiveCN110951741APromotes homologous recombinationStable introduction of DNAVector-based foreign material introductionBase JSingle strand
The invention discloses a bacillus subtilis polygene editing and expression adjusting and controlling system based on CRISPR Cpf1. Through a constructed Cpf1 expression vector pHT-XCR6 and a constructed crRNA array expression vector pcrF11, complete knockout of 2 genes, basic group modification of 6 genes and knock-in of 1 gene can be completed at one time. The vector pHT-XCR6 contains NgAgo protein, and is used for promoting recA mediated homologous recombination. Besides, a vector pLCg6-dCpf1-remA (used for integral expression of a Cpf1 mutant dCpf1 inactivated by deoxyribonuclease and fusion protein of an activating transcription factor remA on a bacillus subtilis genome) and a vector pcra3 (used for integral expression of a crRNA array on the bacillus subtilis genome) are constructed,and can be used for performing transcription inhibition and activation on different genes. The invention further establishes an economic efficient crRNA array assembling method of which the name is SOMACA (Synthetic Oligos Mediated Assembly of crRNA Array), and through synthesizing short-single-strand DNA (60nt ), a needed crRNA array is inserted in the vector pcrF11 or pcra3 and is used for guiding Cpf1 or dCpf1-remA for gene editing and expression adjustment and control.
Owner:JIANGNAN UNIV
Farnesoid x receptor agonists
The present invention relates to famesoid X receptors (FXR, NR1 H4) FXR is a member of the nuclear receptor class of ligand-activated transcription factors. More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same Novel isoxazole compounds are disclosed as part of pharmaceutical compositions for the treatment of a condition mediated by decreased FXR activity, such as obesity, diabetes, cholestatic liver disease and metabolic syndrome.
Owner:GLAXOSMITHKLINE LC
Method and kit for isolating DNA probes that bind to activated transcription factors
Methods, arrays and kits are provided for rapidly and efficiently identifying and quantifying multiple different activated transcription factors in a biological sample at the same time. In one aspect, a method is provided for isolating DNA probes which bind to activated transcription factors, including the step of mixing a library of double stranded DNA probes with a sample containing activated transcription factors. The transcription factor probes that have bound to the activated transcription factors are isolated from the mixture via an agarose gel separation. The bound probes can be identified, for example, by using an array of hybridization probes.
Owner:AFFYMETRIX INC
Use of hepatitis B virus x protein and encoding gene thereof in preparing medicament for treating cancer of liver
ActiveCN101502642AConvenient treatmentGood effectPeptide/protein ingredientsGenetic material ingredientsDrugLiver cancer
The invention belongs to the field of gene therapy of diseases, relating to application of hepatitis B virus x protein gene (HBx) in preparing medicines for treating liver cancer and complicating diseases coupled with the liver cancer. The invention has the technical proposal to provide the application of the hepatitis B virus x protein gene (HBx) and encoded protein thereof in preparing the medicines for treating liver cancer and complicating diseases coupled with the liver cancer. In the invention, the hepatitis B virus x protein gene is recombined into an adenoviral vector to be used in medicines for treating the liver cancer; furthermore, activating transcription factors which are generally considered as virus promoters in the field are creatively engaged in virus pathogenic HBx protein for preparing medicines for treating the liver cancer and are proved to have good effect by in vitro and in vivo experiments, thus being well capable of treating the liver cancer and liver ascites,a complicating disease thereof and providing a new selection for liver cancer treatment in the field.
Owner:SICHUAN UNIV
Method and kit for the determination of cellular activation profiles
InactiveUS20030162211A1Bioreactor/fermenter combinationsBiological substance pretreatmentsBiological activationMolecular biology
The present invention relates to a method for obtaining an activation profile of a biological sample comprising disposing onto a solid support in a pre-determined spatial arrangement a subset of capture molecules able to interact with one or more activated transcription factor(s) present in the biology cell sample, contacting the biological sample upon the solid support under conditions allowing their interaction, monitoring signals resulting from their interaction, and providing a cellular activation profile from the detected signals.
Owner:EPPENDORF ARRAY TECH SA
Cloning and identification of cotton fiber cell secondary wall development-associated GhNAC1 gene
InactiveCN102399792ATranscriptional self-activatingRegulates secondary wall developmentPlant peptidesFermentationExonCell wall
The invention discloses a novel cotton fiber secondary development specific expression gene GhNAC1 full-length sequence, and relates to an important cotton fiber development-associated regulator gene element. The GhNAC1 gene contains three exons and two introns, and is coded with an NAC (N Acetyl L Cysteine) transcription factor. A large quantity of mRNAs (messenger Ribonucleic Acids) of the gene are accumulated specifically at the secondary development stage of the cotton fiber cells, which indicates that the gene is a fiber secondary wall development specific gene. GhNAC1 protein is positioned in a cell nucleolus and has the capability of activating transcription independently, which indicates that the protein serving as a transcription activating factor plays a role in cotton fiber development. GhNAC1 is expressed excessively in arabidopsis, so that leaves crimp upwards, cell walls are thickened, ectopic sedimentation of lignin and the like is detected in foliar epidermic cells, so that the hemicellulose content of foliar cells is greatly increased. As proved by the results, the GhNAC1 can be used for regulating the biosynthesis of cell secondary walls, and plays a key role in the developing process of cotton fiber.
Owner:HUAZHONG NORMAL UNIV
Bacillus pumilus bacterial strain application thereof
ActiveCN104388337ASimple compositionOptimize quantityBacteriaMicroorganism based processesConjugated proteinBacterial strain
The invention aims to provide a bacillus pumilus bacterial strain of which the preservation number is CCTCC M2013263. The bacillus pumilus disclosed by the invention can improve the composition and the number of dominant microbial populations in an alimentary canal of a prawn to form and maintain good microecological balance of the alimentary canal, and withstand the adhesion and the proliferation of viruses in the alimentary canal through competition for nutrition, competition for space or secretion of bacteriocin and the like. The bacillus pumilus can activate the expression of prophenoloxidase, superoxide dismutase, lysozyme, heat shock protein, lipopolysaccharide-glucan conjugated protein, signal transduction and transcriptional activation factors and the like of the prawn with relevant pathogenic infection resistant molecules, and retard the proliferation rate of the viruses in the body of the prawn. The bacillus pumilus disclosed by the invention can be added to raw materials of a prawn feed, and can also be directly applied to the prawn breeding water environment.
Owner:湖北宜水环保科技有限公司
Plasmid carrier pair and immune cells modified by same, and application thereof
InactiveCN110055275ALocal releaseAntibody mimetics/scaffoldsStable introduction of DNAPlasmid VectorPharmaceutical drug
The invention discloses a plasmid carrier pair and immune cells modified by the same, and an application thereof in preparation of drugs for local secretion of IL12 or regulating expression of IL12 and preparation of drugs for enhancing the killing effect of CAR-T cells, and also discloses a composition and combined drug box of the immune cells and the CAR-T cells. The plasmid vector pair includesa first carrier and a second carrier, the first carrier contains a Notch core, and other coding nucleic acid molecules of extracellular and intracellular segments, wherein the intracellular segment preferably contains transcription activating factors; the second carrier contains nucleic acid molecules specifically recognizing and binding with the intracellular segment in the first carrier and nucleic acid molecules encoding IL12. The combined drug box comprises a drug box A containing the immune cells and a drug box B containing the CAR-T cells. The immune cells can control the expression andsecretion of IL12, and have the effect of synergistically treating tumors with the CAR-T cells.
Owner:CRAGE MEDICAL CO LTD
Application of ATF (activating transcription factor) 3 to predicting bladder cancer metastasis and judging prognosis
InactiveCN103235141AInhibit transferImprove prognosis survivalBiological testingBladder cancer patientCancer metastasis
The invention relates to application of an ATF (activating transcription factor) 3 protein to preparation of a kit for detecting or judging bladder cancer metastasis and judging bladder cancer prognosis. The invention also provides the kit for detecting or judging bladder cancer metastasis and judging bladder cancer prognosis. The invention has the following advantages: the invention provides a new protein marker for predicting bladder cancer metastasis of patients with bladder cancers and judging prognosis and the protein marker can be used for detecting or judging bladder cancer invasion and metastasis degrees and judging prognosis by an immunohistochemical detection method; the invention provides the new kit for predicting bladder cancer metastasis of the patients with bladder cancers and judging prognosis; and the invention provides the new application of the ATF 3 protein to suppressing bladder cancer metastasis and lengthening the prognostic lifetime of the patients with bladder cancers.
Owner:XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Use of Activating Transcription Factor-2 (ATF2) for Detecting Skin Cancer
InactiveUS20110129844A1Reduces nuclear localizationHigh expressionMicrobiological testing/measurementDisease diagnosisSuppressorCvd risk
The present invention is based on the discovery of the tumor suppressor role of activating transcription factor 2 (ATF2) in non-melanoma skin cancer development. Accordingly, the invention provides methods of diagnosing a subject as having or at risk of having skin cancer. Also provided are methods of treating skin cancer in a subject, characterizing skin cancer in a subject, and identifying agents useful for treating skin cancer in a subject.
Owner:BURNHAM INST FOR MEDICAL RES
Increased oil content by increasing yap1 transcription factor activity in oleaginous yeasts
Transgenic oleaginous yeast having increased oil content comprising increased Yap1 transcription factor activity, wherein the increased oil content is compared to the oil content of a non-transgenic oleaginous yeast, are described herein. The increased Yap1 transcription factor activity results from overexpressing a Yap1 transcription factor, by increasing the interaction between the transcription factor and a protein that is capable of activating the transcription factor, or by a combination thereof. Methods of using these yeast strains are also described.
Owner:EI DU PONT DE NEMOURS & CO
Human herpes virus hominis pyrolysis, reproduction and activation host marker and purpose thereof
The invention belongs to the technical field of biomedicine, and relates to a human herpes virus hominis pyrolysis, reproduction and activation detection marker, in particular to the purpose of a signal transducer and activator of transcription 6 (Signal transducer and activator of transcription 6,STAT6) as the human herpes virus hominis pyrolysis, reproduction and activation detection marker. Target protein-STAT6 which is consistently regulated during human herpes virus pyrolysis and reproduction is obtained from the host angle, the experiment result shows that the STAT6 protein is significantly reduced in the infection course of Kaposi sarcoma herpesvirus (KSHV), and the STAT6 protein can be used as the marker for detecting pyrolysis, reproduction and activation of various herpes viruses, can be further used as a common target for diagnosing and treating herpes virus relevant tumor diseases, and can be further used for preparing products for preventing, detecting and treating human herpes virus hominis infection.
Owner:FUDAN UNIV
Compounds, kits and methods for conferring cytoprotection
InactiveUS20090155228A1Inhibit transcriptionEasy to testBiocideArtificial cell constructsDiseaseLipid formation
hABCG2, a member of the ATP-Binding Cassette transporters has been identified as a protective pump against endogenous and exogenous toxic agents. ABCG2 was shown to be expressed at high levels in stem cells, and variably regulated during cell differentiation. It is demonstrated herein that functional ABCG2 is expressed in human monocyte-derived dendritic cells by the activation of a nuclear hormone receptor, PPARg. The present results uncovered a mechanism by which up-regulation of functional ABCG2 expression can be achieved via exogenous or endogenous activation of the lipid activated transcription factor, PPARg. Thus the invention relates to combined treatments by PPARg agonists and cytotoxic drugs transportable by ABCG2, various treatments in the field of neoplastic diseases as well as cell therapy, including autologous cell therapy, as well as kits and composition therefor. Method for protecting cells against cytotoxic drugs are also provided.
Owner:UNIVERSITY OF DEBRECEN
Methods of treating metabolic disorders
A method of increasing the insulin sensitivity of insulin resistant cells includes administering to the cells an amount of all-trans-retinoic acid effective to activate transcription factor perosixome proliferator-activated receptor (PPAR) β / δ of the cells.
Owner:CASE WESTERN RESERVE UNIV
Application of duck-derived innate immunomodulatory protein DDX3X
The invention belongs to the field of biotechnology and immunology, and particularly relates to a duck-derived innate immunomodulatory protein DDX3X for regulating and controlling an innate immune signal pathway in duck embryo fibroblasts (DEF), participating in antiviral reaction and playing a role in duck antiviral infection. It is proved in the DEF that overexpression of duck-derived DDX3X caninduce generation of duck I-type interferon by activating transcription factors including IRF1 and Nf-kappa B; after the background expression of DDX3X is interfered, the activity of poly(I: C) and DTMUV induced I-type interferon is also obviously reduced; and the overexpression of DDX3X can be used for remarkably inhibiting the proliferation of the DTMUV (Duck tembusu virus). The invention further discloses that the duck-derived DDX3X is expected to become a novel target for treating duck inflammatory diseases, and can be applied to the preparation of drugs with the effect of inhibiting DTMUVproliferation; the duck-derived DDX3X can also be used as an immunomodulator for duck virus diseases.
Owner:INST OF ANIMAL SCI & VETERINARY HUBEI ACADEMY OF AGRI SCI
Method and kit for the determination of cellular activation profiles
InactiveUS7407748B2Bioreactor/fermenter combinationsBiological substance pretreatmentsBiological activationMolecular biology
The present invention relates to a method for obtaining an activation profile of a biological sample comprising disposing onto a solid support in a pre-determined spatial arrangement a subset of capture molecules able to interact with one or more activated transcription factor(s) present in the biology cell sample, contacting the biological sample upon the solid support under conditions allowing their interaction, monitoring signals resulting from their interaction, and providing a cellular activation profile from the detected signals.
Owner:EPPENDORF ARRAY TECH SA
Mammalian cells for producing a secreted protein
ActiveUS10858653B2Increase productionReduced activityHydrolasesAntibody mimetics/scaffoldsTherapeutic proteinControl cell
The invention relates to the field of cell culture technology. It concerns the knockdown, using RNA interference, or gene knockout, of activating transcription factor 6 beta (ATF6B), or the combination of ceramide synthase 2 (CERS2) and TBC1 domain family member 20 (TBC1 D20) proteins, which play central roles in the cellular secretion pathway. This downregulation leads to improved secretion of biopharmaceutically relevant products produced in mammalian cells. The invention specifically relates to mammalian cells having enhanced secretion of a recombinant therapeutic protein compared to a control cell, a method of producing said mammalian cell, a method for the production of a recombinant secreted therapeutic protein and the use of said mammalian cell for increasing the yield of a recombinant secreted therapeutic protein.
Owner:UNIV STUTTGART +1
Applications of dermal fibroblasts in treating melanomas
ActiveCN111166769APrevent proliferationInhibit migrationUnknown materialsAntineoplastic agentsMelanomaHigh level expression
The invention provides applications of dermal fibroblasts in treating melanomas, and belongs to the technical field of biomedical science. Through the discovery of research, in vitro, the dermal fibroblasts of activating transcription factors 3 with high-level expression can inhibit the proliferation and migration of melanoma cells, and is accompanied by the down-regulation of different cell factors (including IL-6); and in vivo, the dermal fibroblasts expressed by the highly activated transcription factors 3 can reduced the formation of the tumor. In vitro and in vivo effects can be reversedby adding recombinant IL-6 into the melanoma cells, which shows that the activating transcription factor 3 expression of the dermal fibroblasts can adjust the process of the melanomas through IL-6 / STAT3 pathways; and therefore, the dermal fibroblasts have good practical application values.
Owner:SHANDONG UNIV
Methods and pharmaceutical compositions for the treatment of diseases associated with reduced cftr function
Activating transcription factor 6 (ATF6) is involved in cystic fibrosis transmembrane conductance regulator (CFTR) repression and understanding this inhibitory mechanism is of great interest to develop a therapeutic approach based on UPR regulation. Using site-1 protease (S1P) inhibitor (e.g. PF-429242) the inventors showed that both membrane localization and function of F508del-CFTR are partially restored. Accordingly, the present invention relates to a method of treating a disease associated with reduced CFTR function in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a S1P inhibitor.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3
Application of dermal fibroblasts in the treatment of melanoma
ActiveCN111166769BPrevent proliferationInhibit migrationUnknown materialsAntineoplastic agentsMelanomaHigh level expression
Owner:SHANDONG UNIV
Application of micropeptide ASRPS in treating cancer
ActiveCN110215511ASuppress generationHas clinical medicinal valuePeptide/protein ingredientsAntineoplastic agentsVegf pathwayAngiogenesis growth factor
The invention relates to application of micropeptide ASRPS in treating cancer. From the perspective of the translation level of the micropeptide encoded by lncRNA, the influence of the micropeptide onangiogenesis of triple negative breast cancer is studied, and the important role of the micropeptide in triple negative breast cancer is demonstrated. The micropeptide ASRPS affects angiogenesis of triple negative breast cancer, and the signal transduction and the activation of an activating transcription factor 3 (STAT3) are thus influenced by changing the expression amount of the micropeptide,so that the expression of a vascular endothelial growth factor (VEGF) is influenced, and the angiogenesis capability of triple negative breast cancer is influenced. It is proved by in-vivo and in-vitro experiments that the micropeptide ASRPS obviously inhibits angiogenesis of breast cancer through a STAT3-VEGF pathway, and the micropeptide ASRPS has a clinical medicinal value for treating triple negative breast cancer.
Owner:SUZHOU UNIV
Atf6 inhibitors and uses thereof
Compounds as inhibitors of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.
Owner:PRAXIS BIOTECH LLC
ATF6 inhibitors and uses thereof
Compounds as inhibitors of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer.
Owner:ALTOS LABS INC
Recombinant TAT-HOX family protein with N-terminal labeled histamine acid and its preparation
PendingCN111434694APolypeptide with localisation/targeting motifPeptide preparation methodsEscherichia coliHOXA4
The invention relates to a recombinant HOX family protein containing labeled histamine acid and activator of transcription (TAT) fragment at an N-terminal, the N-terminal containing at least six histamine acid residues and Tat fragments. N-terminally labeled histidine TAT-HOX family recombinant proteins (His-TAT-HOX family proteins) made according to the present invention include recombinant His-TAT-HOXA4, His-TAT-HOXC4, His-TAT-HOXD4, His-TAT-HOXB3, His-TAT-HOXB6 and the like, and after the recombinant proteins are expressed in escherichia coli host cells and purified, the recombinant proteins have the capacity of proliferating hematopoietic stem cells. The invention also discloses a preparation method and a composition of the His-TAT-HOX family recombinant proteins.
Owner:TAIWAN ADVANCE BIO PHARM INC
Method and kit for the determination of cellular activation profiles
InactiveUS20090082223A1Peptide librariesMicrobiological testing/measurementBiological activationMolecular biology
A method for obtaining an activation profile of a biological sample by disposing onto a solid support in a pre-determined spatial arrangement a subset of capture molecules able to interact with one or more activated transcription factor(s) present in the biological sample, contacting the biological sample upon the solid support under conditions allowing their interaction, monitoring signals resulting from their interaction, and providing a cellular activation profile from the detected signals.
Owner:EPPENDORF ARRAY TECH SA
Progesterone whole-cell biosensor as well as preparation method and application thereof
PendingCN114507294AAccurate detectionQuick checkFungiFusion with DNA-binding domainProgesteronesProgestogen
Owner:EAST CHINA UNIV OF SCI & TECH
Sequencing method of rice bacterial leaf blight activating transcription factor like effector gene
InactiveCN103361400AEfficient separationPrecise sequencingMicrobiological testing/measurementMicroorganism based processesTAL effectorBlight
The invention provides a sequencing method of rice bacterial leaf blight activating transcription factor like effector gene, can effectively separate repeating region of nearly each TAL effector family gene, performs accurate sequencing and assembly to the TAL effector family gene, and provides essential support for the functional research and application of TAL effectors.
Owner:GUANGXI UNIV
Anti-stat3 bispecific antibody having cell-penetrating ability, and pharmaceutical composition containing same
PendingCN111699002AOvercome limitationsAvoid developmentAntipyreticAnalgesicsAntiendomysial antibodiesTranscription factor activity
The present invention relates to an anti-STAT3 bispecific antibody having a cell-penetrating ability, and a pharmaceutical composition containing same and, more specifically, to an anti-STAT3 bispecific antibody comprising a site specifically binding to STAT3 and a DNA binding site enabling cell-penetration, and a pharmaceutical composition containing same as an active ingredient. It has been ascertained that a STAT3 / DNA bispecific antibody according to the present invention comprises a DNA binding site, which allows penetration into cells and specifically binds to intranuclear DNA, so as to be capable of overcoming limitations of a conventional antibody drug, which only targets proteins existing outside the cells, and binds specifically only to STAT3 in the active phosphorylated form so as to be capable of inhibiting the transcription factor activity thereof, thereby being effectively usable in the development of: therapeutic agents, having no side effects, for associated diseases caused by the activation of STAT3, for example, therapeutic agents for various carcinomas associated with the activation of STAT3; drugs capable of inhibiting cancer metastasis induced by the activationof STAT3; and therapeutic agents, having no side effects, for inflammatory diseases caused by the activation of STAT3, including rheumatoid arthritis.
Owner:罗菲佰欧株式会社
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com